KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma

KMT2C is a Potential Biomarker of Anti-PD-1 Treatment Response in Metastatic Melanoma

Background: Metastatic melanoma (MM) represents a common malignancy with poor prognosis. Immune checkpoint inhibition (ICI), including PD-1 blockade, has been emerging as the popular therapeutic in MM for its durable treatment effect, but its response rate is still limiting. Methods: We comprehensiv...

Full description

Bibliographic Details
Main Authors: Kuixia Xie, Yonglin Peng, Wenying Zhong, Xinhua Liu
Format: Article
Language:English
Published: IMR Press 2022-03-01
Series:Frontiers in Bioscience-Landmark
Subjects:
metastatic melanoma
immune checkpoint
pd-1
kmt2c
tumor microenvironment
neoantigen
Online Access:https://www.imrpress.com/journal/FBL/27/3/10.31083/j.fbl2703103

Similar Items

Similar Items